Phase 2 × Lymphoma, Mantle-Cell × ibritumomab tiuxetan × Clear all A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
Phase 2 Completed
41 enrolled 10 charts
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Phase 2 Completed
46 enrolled 5 charts
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Phase 2 Completed
5 enrolled 8 charts
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 2 Completed
122 enrolled 16 charts
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
42 enrolled 11 charts
ZEVALLO
Phase 2 Completed
31 enrolled
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Phase 2 Terminated
5 enrolled 8 charts
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Phase 2 Completed
30 enrolled
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2 Completed
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma
Phase 2 Completed
160 enrolled
LCM-04-02
Phase 2 Completed
30 enrolled
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Phase 2 Completed
35 enrolled